Access to health

An estimated 1.3 billion people have no access to effective and affordable healthcare. According to the World Health Organization (WHO), developing countries bear 93% of the world’s disease burden, yet account for only 18% of world income and 11% of global health spending. Providing access to health in these countries is a complex challenge. Improving access involves researching, developing and refining health solutions, creating efficient health systems and distribution channels, offering products at affordable prices and empowering health workers and patients.

Strategic approach

Clinical trials

As regards clinical trials, we adhere to all applicable statutory regulations and industry standards, such as Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. Our clinical trials are performed according to the same high ethical and scientific standards in all countries worldwide.

Read more under Clinical trials.

Responsible Marketing

In order to ensure professional and transparent conduct in our pharmaceutical marketing activities, we comply not only with numerous statutory regulations, but have also defined our own code of practice.

Read more under Responsible marketing

Counterfeit medicines

Counterfeit medicines pose a major global threat to public health. The World Health Organization (WHO) estimates that a number of pharmaceuticals available on the market in developing countries are illegal, counterfeit or substandard. We fight product-related crime in order to protect patients, our customers, and our company’s reputation.

Read more under Product-related crime


Publication of Merck KGaA, Darmstadt, Germany.

In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

Chart Generator

Interactive chart tool